Zyvox Sales Data
| Rank 92 | Current sales rank, all U.S. Pharmaceuticals. |
Last updated: May 2013 (updated quarterly).
The following data shows Zyvox U.S. retail sales in Q1 2013 compared to previous quarters.
| Date Range | Sales Rank | Sales ($000) | Units (000) | ||
|---|---|---|---|---|---|
| Q1 2013 | 92 ( 5) |
$188,084 | 11.15% | 142 | 11.81% |
| Q4 2012 | 97 (1) |
$169,211 | -1.48% | 127 | -1.55% |
| Q3 2012 | 98 ( 7) |
$171,755 | -1.37% | 129 | -8.51% |
| Q2 2012 | 91 | $174,134 | -3.00% | 141 | -2.76% |
| Q1 2012 | 91 (2) |
$179,523 | 3.85% | 145 | 3.57% |
| Q4 2011 | 93 (5) |
$172,862 | 1.17% | 140 |  |
| Q3 2011 | 88 (3) |
$170,871 | -3.78% | 140 | -9.68% |
| Q2 2011 | 91 (9) |
$177,583 | -4.59% | 155 | -6.06% |
| Q1 2011 | 82 | $186,128 | |
165 | |
* Units refer to the number of packages sold.
Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.
See Also
Related News
| Date | Article |
|---|---|
| July 27, 2011 | FDA MedWatch - Zyvox (linezolid): Drug Safety Communication - Serious CNS Reactions Possible When Given to Patients Taking Certain Psychiatric Medications |
